Spotlights

Euroclear&Avanza

AUXESIS PHARMA HOLDING AB (publ) is now a settlement company and started with Euroclear as the securities institution and Avanza Bank as the company’s Issuance

Read More »

Production Site

Östersund AUXESIS PHARMA HOLDING AB (publ) is in the establishment phase of pharmaceutical manufacturing in Östersund, Sweden.  In September 2023 the company will submit an

Read More »

Protocol AGM 2023

Protocol from The AUXESIS PHARMA HOLDING AB (publ) Annual General Meeting 2023 is now available for download in the Investor Hub.

Read More »

Annual report

AUXESIS PHARMA HOLDING (publ) Annual report /Årsredovisning and associated documents regarding the Annual Meeting is now available for download in the Investor Hub for investors.

Read More »

Pitch update

New updated Pitch, Memorandum and Scenario Valuation 2023 for download. Auxesis Pharma Pitch 2023 Download here Auxesis Pharma Memorandum 2023 Download here Auxesis Pharma Scenario

Read More »

Avanza

Euroclear AUXESIS PHARMA HOLDING AB (publ) has now entered into an agreement with the issuance institute Avanza Sweden. All shareholders will be registered with Euroclear

Read More »

Scenario valuation 2023

Valuation AUXESIS 03/2023 Scenario valuation of the shares in AUXESIS PHARMA HOLDING AB (publ) prior to the launch of the company’s analgesic product ASA.P® is

Read More »

Investor Forum

Investor Invitation We are excited to invite you to our first Investor Forum monday the 30th of january at the Karolinska Institute, Huddinge, Sweden. On

Read More »